CardioGenics Holdings Inc. is focused on technology and products targeting the immunoassay segment of the In-Vitro Diagnostic testing market. The Company has developed the QL Care Analyzer, a point-of-care immuno-analyzer, which is capable of running approximately 200+immunoassay diagnostic tests, such as cardiovascular diagnostic tests. As part of its technology, the Company has also developed a method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improves instrument sensitivity to light.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Market Cap	382K 331K 309K 283K 533K 36.37M 541K 3.62M 1.42M 18.23M 1.44M 1.4M 60.27M	P/E 2014	-2.3x	P/E 2015	-2.17x
Enterprise Value	539K 466K 435K 399K 751K 51.27M 763K 5.11M 2M 25.7M 2.02M 1.98M 84.95M	EV / Sales 2014	-	EV / Sales 2015	-
Free-Float	97.49%	Yield 2014 *	-	Yield 2015	-

10/09/21	Cardiogenics Holdings Inc Announces A Record Date Change for Its Dividend Distribution	CI
04/09/21	CardioGenics Holdings Inc. Announces License Agreement	CI
02/11/15	CardioGenics Holdings Inc completed the acquisition of substantially all of the assets of Plasticap Inc.	CI
05/10/15	CardioGenics Holdings Inc entered into a non-binding letter of intent to acquire substantially all of the assets of Plasticap Inc.	CI
13/01/15	CardioGenics Holdings Inc. Appoints Karim Murabet as Director	CI
27/09/13	CardioGenics Holdings Inc Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2013	CI
21/08/13	CardioGenics Holdings Inc Announces Commencement of Beta-Site Testing	CI
05/06/13	CardioGenics Holdings Inc Announces Internal Review Board Approval for Beta-Site Testing	CI
03/06/13	CardioGenics Holdings Inc announced that it has received $0.66 million in funding.	CI
31/05/13	CardioGenics Holdings Inc announced that it expects to receive $1.5 million in funding.	CI
01/03/13	CardioGenics Holdings Inc. Announces Demise of Director, Alexander D. G. Reid	CI
27/02/13	CardioGenics Holdings Inc. announced that it expects to receive $1 million in funding.	CI
17/04/12	CardioGenics Holdings Inc has Changed its Ticker to CGNH from CGNHE	CI

29/09/21	UPDATED: CARDIOGENICS HOLDINGS INC. ANNOUNCES A RECORD DATE CHANGE FOR ITS DIVIDEND DISTRIBUTION	AQ
10/09/21	CARDIOGENICS : ANNOUNCES A RECORD DATE CHANGE FOR ITS DIVIDEND DISTRIBUTION	AQ
04/09/21	CARDIOGENICS : ANNOUNCES LICENSE AGREEMENT AND DIVIDEND DISTRIBUTION	AQ
04/11/15	CardioGenics : Enters Into Asset Purchase Agreement to Acquire All Assets of Ontario-Based Plasticap	MW
05/10/15	CardioGenics : Enters Into Binding Letter of Intent to Acquire Assets of Ontario-Based Plasticap	MW

Manager	Title	Age	Since
Yahia A. Gawad CEO	Chief Executive Officer	68	27/10/2009
James A. Essex DFI	Director of Finance/CFO	78	16/06/2010
Linda J. Sterling IRC	Investor Relations Contact	65	-

Director	Title	Age	Since
Yahia A. Gawad BRD	Director/Board Member	68	06/04/2011
Julian Neil Tabatznik CHM	Chairman	76	16/06/2010
Linda J. Sterling BRD	Director/Board Member	65	16/06/2010

CardioGenics Holdings Inc Stock Other OTC

Stocks

CGNH

US14160X2036

Medical Equipment, Supplies & Distribution

Valuation: CardioGenics Holdings Inc

Latest news : CardioGenics Holdings Inc

Press Releases: CardioGenics Holdings Inc

Quotes and Performance

Managers and Directors: CardioGenics Holdings Inc

Diagnostic & Testing Substances

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CARDIOGENICS HOLDINGS INC	-35.19%	+110.24%	-	-	14.29K
GUARDANT HEALTH, INC.	+6.92%	+4.01%	+210.68%	+362.10%	22.61B
BIOMÉRIEUX	+0.48%	+5.43%	-41.58%	-22.48%	9.91B
10X GENOMICS, INC.	+14.10%	+10.07%	+323.35%	-0.61%	6.78B
LANTHEUS HOLDINGS, INC.	-0.12%	+1.31%	+76.49%	+46.69%	6.59B
CARIS LIFE SCIENCES, INC.	+13.70%	+45.12%	-23.56%	-	6.43B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	+2.88%	+0.88%	-12.31%	-12.87%	5.62B
ANDON HEALTH CO., LTD.	+1.75%	+6.08%	+83.15%	+103.36%	4.51B
DIASORIN S.P.A.	+1.26%	+4.93%	-9.05%	-20.46%	4.31B
AUTOBIO DIAGNOSTICS CO., LTD.	+1.31%	-2.05%	-20.81%	-36.22%	2.75B
Average	+0.71%	+8.76%	+65.15%	+52.44%	7.72B
Weighted average by Cap.	+5.43%	+8.32%	+102.22%	+134.32%

	2014	2015
Net sales	-	-
Net income	-2.68M -2.32M -2.16M -1.99M -3.74M -255M -3.79M -25.4M -9.97M -128M -10.06M -9.84M -423M	-1.92M -1.66M -1.55M -1.42M -2.67M -182M -2.71M -18.16M -7.13M -91.41M -7.2M -7.04M -302M
Net Debt	132K 114K 107K 97.99K 184K 12.59M 187K 1.25M 492K 6.31M 497K 486K 20.85M	157K 135K 126K 116K 218K 14.9M 222K 1.48M 582K 7.47M 588K 575K 24.68M